News|Articles|February 20, 2025

Pharma Pulse 2/20/25: Popping the Gross-to-Net Bubble, Prompting Better Care with Question Prompt Lists & more

The latest news for pharma industry insiders.

Popping the Gross-to-Net Bubble, Part II: What Manufacturers Can Do About It

Welcome to the second installment of the “Popping the Gross-to-Net Bubble” series. In this column, I’ll dive into actionable steps pharmaceutical manufacturers can take to address this issue. This series is not intended as an academic review of the concept or problem but rather as a practical toolset for commercial teams, drawing from my 25 years of experience working on these challenges.

Prompting Better Care: Improving Conversations with Question Prompt Lists

QPL use in the pharmacy setting may enhance patient engagement while allowing pharmacists to showcase their medication-related expertise.

AI Data Center With Up to 3 Gigawatts of Power Is Envisioned for South Korea

Few global facilities possess more than a gigawatt of power, making electricity for AI computing increasingly scarce.

Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

Hims & Hers Health, Inc. plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making.

Andy Woolf on LinkedIn

Excellent photo - look forward to reading the article!

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.